Kidney Cancer
Conditions
Interventions
case series:No
Sponsors
Renji Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary participation in this study and signing the informed consent form; 2. Male or female, aged 18 years or older and under 80 years; 3. Diagnosed as clear cell carcinoma or clear cell carcinoma predominant renal cell carcinoma through histopathological examination; 4. Clinical CT or MR staging as any TN1M0 or any TN0M1; IMDC score = 3.5 × 10^9/L, absolute neutrophil count >= 1.5 × 10^9/L, PLT >= 75.0 × 10^9/L, HGb >= 80g/L; - Cardiac function: Cardiac function 0-2 grades; - Liver function: Total bilirubin = 45 ml/min; 8. Willing and able to follow the trial and follow-up procedures.
Exclusion criteria
Exclusion criteria: 1. Non-transparent cell carcinoma; 2. Severe liver and kidney dysfunction, combined with other serious diseases; 3. Known to have severe cardiovascular diseases, including any of the following conditions: a myocardial infarction or arterial inflammation or venous thrombosis event (such as pulmonary embolism) occurred in the past 1 year; severe/ unstable angina pectoris; uncontrollable hypertension; heart failure, reaching NYHA standard level III or IV; drug-induced ventricular arrhythmia; 4. History of immunodeficiency diseases (including positive HIV test, other acquired or congenital immune deficiency diseases) or history of organ transplantation or autoimmune diseases; 5. History of severe central nervous system diseases. History of epilepsy or any disease that may induce epilepsy, including unexplained loss of consciousness or transient ischemic attack; 6. Combined with other malignant tumors in the past 5 years, except for cured skin basal cell carcinoma and cervical carcinoma in situ; 7. Unable to cooperate with regular follow-up observation due to psychological, social, family and geographical reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic Accuracy of Serum Biomarker Signature in Predicting Response to Immunotherapy;Correlation Between Serum Biomarker Levels and Objective Response Rate (ORR) ;Association of Serum Biomarker Signatures with Progression-Free Survival (PFS);Sensitivity;Speciificity; | — |
Countries
China
Contacts
Public ContactZhai Wei
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed